Best Momentum Stocks to Buy for July 17th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 17th:

ProKidney Corp. PROK: This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.8% over the last 60 days.

ProKidney Corp. Price and Consensus

ProKidney Corp. price-consensus-chart | ProKidney Corp. Quote

ProKidney’s shares gained 371.7% over the last three months compared with the S&P 500’s advance of 18.2%. The company possesses a Momentum Score of A.

ProKidney Corp. Price

ProKidney Corp. price | ProKidney Corp. Quote

Roku, Inc. ROKU: This operator of a TV streaming platform has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.3% over the last 60 days.

Roku, Inc. Price and Consensus

Roku, Inc. price-consensus-chart | Roku, Inc. Quote

Roku’s shares gained 55.4% over the last three months compared with the S&P 500’s advance of 18.2%. The company possesses a Momentum Score of B.

Roku, Inc. Price

Roku, Inc. price | Roku, Inc. Quote

Pharming Group N.V. PHAR: This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 7% over the last 60 days.

Pharming Group N.V. Sponsored ADR Price and Consensus

Pharming Group N.V. Sponsored ADR price-consensus-chart | Pharming Group N.V. Sponsored ADR Quote

Pharming’s shares gained 26.6% over the last three months compared with the S&P 500’s advance of 18.2%. The company possesses a Momentum Score of B.

Pharming Group N.V. Sponsored ADR Price

Pharming Group N.V. Sponsored ADR price | Pharming Group N.V. Sponsored ADR Quote

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research